Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NETs and endocrine tumours

2867 - Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial

Date

22 Oct 2018

Session

Poster Discussion session - NETs and endocrine tumours

Presenters

Anja Rinke

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

A. Rinke1, M.P. Neary2, J. Eriksson3, M. Hunger4, T. Doan5, D. Karli5, R. Arnold1

Author affiliations

  • 1 Department Of Gastroenterology And Endocrinology, Philipps-University of Marburg, 35043 - Marburg/DE
  • 2 Global Value And Access, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 3 Rwes&a, Mapi (ICON plc), Stockholm/SE
  • 4 Rwes&a, Mapi (ICON plc), Munich/DE
  • 5 Product Lifecycle Services, Novartis Ireland Ltd., Dublin/IE
More

Resources

Abstract 2867

Background

In phase IIIb PROMID, oct l-a (30mg intramuscular/monthly) significantly extended time to tumor progression (HR = 0.34; 95% CI: 0.20, 0.59; p = 0.000072) compared with PBO in treatment-naïve pts with well-differentiated mmNETs. We report post-hoc analyses for HRQoL.

Methods

HRQoL was measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30), a 30-item self-report questionnaire with 5 functional, 1 global, and 9 symptom scales. Assessments were completed at baseline and every 12 wks until tumor progression. Time to definitive deterioration (TDD) was analyzed with the Kaplan-Meier method (using ≥10 points minimal important difference, range 0-100); distributions were compared using a stratified log-rank test adjusting for tumor functionality. Linear mixed models were fit to assess change from baseline in QLQ-C30 scores by treatment arm over time.

Results

Of 85 pts enrolled between 2001 and 2008, 82 (96%) completed the QLQ-C30 at baseline (oct l-a: 40, PBO: 42). There were few events of definitive deterioration for most scales. Median TDD was not reached in 11/15 scales for oct l-a and 5/15 scales for PBO. Significantly longer TDD was reported for oct l-a vs. PBO for fatigue (median 6.8 months vs 18.5; p = 0.0006), pain (not reached (NR) vs 18.2; p = 0.0435), and insomnia (NR vs 16.4; p = 0.0046). Change from baseline to wk 24 fatigue scores were stable for oct l-a (least squares [LS] mean 0.78 (95% CI -6.3: 7.8) but worsened for PBO (LS mean 9.1; 95% CI 1.9: 16.4); with mean difference -8.4 (95% CI -18.5: 1.8). For diarrhea there were improvements for oct l-a (LS mean -8.0; 95% CI -19.6: 3.5) and worsening for PBO (LS mean 11.2; 95% CI -0.7: 23.1); with mean difference -19.3 (95% CI: -36.1; -2.5).

Conclusions

These post-hoc analyses showed significantly longer TDD for oct l-a vs. PBO in pts with mmNET for symptoms relevant in NET: fatigue, pain, and insomnia; alongside improved tumor control. Change from baseline showed that HRQoL was maintained in oct l-a pts whereas significant deterioration for some symptoms was observed in PBO pts, further supporting HRQoL benefits of oct l-a treatment.

Clinical trial identification

SMS995ADE05 / NCT00171873.

Legal entity responsible for the study

Novartis Pharmaceuticals Incorporated.

Funding

Novartis Pharmaceutical Corporation.

Editorial Acknowledgement

Disclosure

A. Rinke: Advisory boards: Novartis, Ipsen. M.P. Neary: Employee: Novartis Pharmaceuticals Corporation. J. Eriksson, M. Hunger: Employee: ICON plc. T. Doan, D. Karli: Employee: Novartis Ireland Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings